The KCTD9 Knockout 143B Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of 143B osteosarcoma cells with targeted disruption of the KCTD9 gene. This heterogeneous cell pool provides a versatile model for studying the consequences of KCTD9 loss-of-function in a tumorigenic background. The polyclonal format preserves a breadth of genetic variation associated with CRISPR-mediated gene ablation, enabling robust comparative analyses between wild-type 143B cells and a mixed population of KCTD9-deficient counterparts. Researchers can employ these cells to dissect KCTD9-dependent regulatory mechanisms.
The 143B host cell line is a well-established human osteosarcoma model derived from HOS. These fibroblast-like cells exhibit high tumorigenicity and metastatic potential in vivo, making them a relevant system for bone cancer research. Their rapid proliferation and aggressive phenotype facilitate studies of tumor progression, invasion, and metastasis. The 143B background provides a pathologically relevant context for investigating the interplay between the ubiquitin-proteasome system and oncogenic signaling, particularly in the bone microenvironment.
KCTD9 functions as a substrate-specific adaptor for the CUL3-RING E3 ubiquitin ligase complex. Mechanistically, KCTD9 recruits TRIF, a critical adaptor protein in Toll-like receptor 3 and 4 (TLR3/4) signaling, and promotes its ubiquitination and proteasomal degradation, thereby limiting downstream activation of TRAF6, TAK1, and NF-??B. Concurrently, KCTD9 also targets SMAD2 and SMAD3 for ubiquitination, attenuating TGF-?? signaling. This positions KCTD9 as a converging negative regulator of both innate immune and fibrotic responses, interacting directly with CUL3 to modulate turnover of these key signal transducers.
In the context of 143B osteosarcoma cells, the loss of KCTD9 is predicted to enhance both TLR3/4- and TGF-??-driven pathways. Enhanced TGF-?? signaling is a known driver of osteosarcoma metastasis, epithelial-mesenchymal transition, and extracellular matrix remodeling. Dysregulated TLR signaling may alter the inflammatory tumor microenvironment. Thus, this knockout model offers a unique tool for elucidating how KCTD9 integrates these oncogenic signals to control tumor aggressiveness and metastatic dissemination.
Transcriptional profiling by RT-qPCR and RNA-seq monitors gene expression changes upon KCTD9 ablation, while western blotting detects TRIF, SMAD2/3, and downstream effectors. Migration and invasion assays, with TGF-?? reporters, assess metastatic potential. Co-immunoprecipitation and ubiquitination assays validate KCTD9 interactions with CUL3 and substrate ubiquitination status. Flow cytometry for NF-??B activation monitors TLR pathway output. These polyclonal knockout cells enable comprehensive investigation of ubiquitin-dependent signaling in osteosarcoma. For further product information, please contact Ascent Research.
